Olesnicky G, Long A R, Quinn M A, Pepperell R J, Horacek I, Kneale B L
Aust N Z J Obstet Gynaecol. 1985 Feb;25(1):7-16. doi: 10.1111/j.1479-828x.1985.tb00594.x.
In a retrospective study of 455 patients with confirmed molar pregnancy, registered with the Hydatidiform Mole Register of the State of Victoria in the years 1973-1982 inclusive, treatment for persistent trophoblastic activity was necessary in 62 (13.6%) patients. The need for treatment was independent of levels of urinary chorionic gonadotrophin (UCG) excretion prior to evacuation of the molar pregnancy, age, parity or blood group. All patients achieved initial remission of UCG levels within 5 courses of treatment. Risk factors were scored retrospectively and patients responded poorly if therapy inappropriate to risk factors was given. Only 2 cases of histologically proven choriocarcinoma occurred and the only death recorded was in 1 of these patients.
在一项针对455例确诊为葡萄胎妊娠患者的回顾性研究中，这些患者于1973年至1982年（含）期间在维多利亚州葡萄胎登记处登记，62例（13.6%）患者需要针对持续性滋养层细胞活性进行治疗。治疗需求与葡萄胎妊娠排空前的尿绒毛膜促性腺激素（UCG）排泄水平、年龄、产次或血型无关。所有患者在5个疗程内均实现了UCG水平的初始缓解。对风险因素进行了回顾性评分，如果给予的治疗与风险因素不匹配，患者的反应较差。仅发生了2例经组织学证实的绒毛膜癌病例，记录的唯一死亡病例是其中1例患者。
